MedTrace Logo

A Study of MI226 Injection for Abdominal Fat Accumulation

NCT07749742 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-08-06

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind (with open-label sentinel cohorts), placebo-controlled, single-ascending-dose study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of MI226 Injection in participants with abdominal fat accumulation.

Conditions

  • Abdominal Fat

Interventions

DRUG

MI226 Injection（dose 3）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 injection（dose 4）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 injection（dose 5）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 Injection（dose 6）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 Injection（dose 7）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 injection（dose 8）

Single injection into the subcutaneous adipose tissue.

DRUG

Placebo

Placebo

DRUG

MI226 Injection（dose 2）

Single injection into the subcutaneous adipose tissue.

DRUG

MI226 injection（dose 1）

Single injection into the subcutaneous adipose tissue.

Sponsors & Collaborators

  • Nanjing Minova Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-28
Primary Completion
2027-02-28
Completion
2027-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07749742 on ClinicalTrials.gov